Osimertinib early dose reduction as a risk to brain metastasis control in EGFR-mutant non-small cell lung cancer.

Takehiro TozukaRintaro NoroAkihiko MiyanagaShinji NakamichiSusumu TakeuchiMasaru MatsumotoKaoru KubotaKazuo KasaharaMasahiro Seike

Published in: Cancer medicine (2023)

Early dose reduction of osimertinib was a risk factor for the worsening of BMs. A higher risk was associated with younger patients and those presenting BMs before treatment.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
end stage renal disease
advanced non small cell lung cancer
newly diagnosed
ejection fraction
prognostic factors
white matter
case report
multiple sclerosis
patient reported outcomes
blood brain barrier
patient reported